These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

72 related items for PubMed ID: 21854086

  • 21. Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
    Ramanarayanan J, Mehdi S, Brodzik F, Pasquale D.
    Hematology; 2007 Dec; 12(6):505-9. PubMed ID: 17852464
    [Abstract] [Full Text] [Related]

  • 22. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA, Pan Q, Ladanyi M, Steinherz PG.
    Cancer; 2003 Dec 15; 98(12):2643-50. PubMed ID: 14669284
    [Abstract] [Full Text] [Related]

  • 23. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
    Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brøndum-Nielsen K.
    Leukemia; 2002 Jul 15; 16(7):1390-3. PubMed ID: 12094265
    [No Abstract] [Full Text] [Related]

  • 24. When evaluating parameter uncertainty is not enough: the case of dasatinib and nilotinib for imatinib-resistant chronic myeloid leukemia.
    Reed SD.
    Value Health; 2011 Dec 15; 14(8):1055-6. PubMed ID: 22152174
    [No Abstract] [Full Text] [Related]

  • 25. Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML).
    Patchenko P, Klepfish A, Trakhtenbrot L, Rothman R, Rachmilewitz EA.
    Am J Hematol; 2004 Dec 15; 77(4):420. PubMed ID: 15558793
    [No Abstract] [Full Text] [Related]

  • 26. Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
    De Melo VA, Milojkovic D, Khorashad JS, Marin D, Goldman JM, Apperley JF, Reid AG.
    Blood; 2007 Oct 15; 110(8):3086-7. PubMed ID: 17916757
    [No Abstract] [Full Text] [Related]

  • 27. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q, Chen SS, Jiang B, Jiang H, Lu Y, Qiu JY, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 15; 26(1):23-6. PubMed ID: 15946504
    [Abstract] [Full Text] [Related]

  • 28. Trisomy 8 in Philadelphia-negative cells during imatinib therapy.
    Bernardeschi P, Fiorentini G, Rossi S, Dentico P, Simi P, Guidi S.
    Am J Hematol; 2004 Sep 15; 77(1):88-9. PubMed ID: 15307114
    [Abstract] [Full Text] [Related]

  • 29. Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
    Zámecníkova A, Al Bahar S, Ramesh P.
    Leuk Res; 2008 Sep 15; 32(9):1454-7. PubMed ID: 18294688
    [Abstract] [Full Text] [Related]

  • 30. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
    Eskazan AE, Ayer M, Kantarcioglu B, Arica D, Demirel N, Aydin D, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T.
    Br J Haematol; 2014 Oct 15; 167(1):139-41. PubMed ID: 24815307
    [No Abstract] [Full Text] [Related]

  • 31. Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation.
    Yasuda H, Aritaka N, Ando J, Hirama M, Komatsu N, Hirano T.
    Intern Med; 2011 Oct 15; 50(5):501-2. PubMed ID: 21372467
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase.
    Dybko J, Haus O, Jazwiec B, Urbaniak J, Wozniak M, Kaczmar-Dybko A, Urbaniak-Kujda D, Kapelko-Slowik K, Kuliczkowski K.
    Acta Haematol; 2014 Oct 15; 132(2):166-71. PubMed ID: 24577437
    [Abstract] [Full Text] [Related]

  • 39. Dramatic resolution of respiratory symptoms with imatinib mesylate in patients with chronic myeloid leukemia presenting with lower airway symptoms resembling asthma.
    Ramanujam D, McNicholl F, Furby D, Richardson D, Cuthbert RJ, McMullin MF.
    Leuk Lymphoma; 2009 Oct 15; 50(10):1721-2. PubMed ID: 19757309
    [No Abstract] [Full Text] [Related]

  • 40. Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia.
    Slager SL, Skibola CF, Di Bernardo MC, Conde L, Broderick P, McDonnell SK, Goldin LR, Croft N, Holroyd A, Harris S, Riby J, Serie DJ, Kay NE, Call TG, Bracci PM, Halperin E, Lanasa MC, Cunningham JM, Leis JF, Morrison VA, Spector LG, Vachon CM, Shanafelt TD, Strom SS, Camp NJ, Weinberg JB, Matutes E, Caporaso NE, Wade R, Dyer MJ, Dearden C, Cerhan JR, Catovsky D, Houlston RS.
    Blood; 2012 Jul 26; 120(4):843-6. PubMed ID: 22700719
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.